Dymicron Launches Regulation A+ Equity Crowdfunding Investment Offering

Company Seeks $15.8 million for FDA trial and international expansion with Triadyme®-C cervical total disc replacement

Dymicron today announced that it is launching an offering of securities through the use of an offering statement that has been qualified by the Securities and Exchange Commission.

Dymicron has partnered with DealMaker for its self-hosted $15.8 million raise. Regulation A+ raise. Regulation A+ is a relatively new exemption which allows private companies to sell their shares to unaccredited investors. “Medical Device companies have recently found this approach to fundraising attractive to investors and we are proud to be one of the leaders in the medical device industry to be on the forefront of this movement to democratize the capital fundraising process” said Alan Layton Chairman and CEO.

About Triadyme® – C
The Triadyme-C is a motion preserving cervical artificial disc made of polycrystalline diamond, one of the most robust and durable materials known to mankind. As a result, the Tri­adyme-C produces virtually no detectable wear, minimizing the risk of any wear debris-related complications, ensuring performance for the lifetime of the patient. The Triadyme-C’s patented Tri-Lobe design mimics the natural kinematics and motion of a normal disc.

SourceDymicron

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version